### General description

Clindamycin is a lincosamide antibiotic with activity against gram-positive cocci and many anaerobes.

<table>
<thead>
<tr>
<th>INN</th>
<th>Clindamycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>J01FF01</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>Antibiotic groups</td>
<td>ACCESS</td>
</tr>
</tbody>
</table>
| EML status history | First added in 1991 (TRS 825) for Bacterial infection of unspecified site  
Added in 2017 (TRS 1006) for Osteomyelitis or osteitis  
Added in 2017 (TRS 1006) for Bacterial infection of joint  
Removed in 2017 (TRS 1006) for Bacterial infection of unspecified site  
Added in 2021 for Necrotising fasciitis |
| Wikipedia | Clindamycin |
| DrugBank  | Clindamycin |

### Recommendations

**Section**  
Access group antibiotics

| Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)  
Oral > Solid: 150 mg (as hydrochloride) capsule  
Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection  
Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)  
Oral > Solid: 150 mg (as hydrochloride) |

**Indications**

First choice  
co-prescribed with piperacillin + tazobactam  
Necrotising fasciitis

Second choice  
Bacterial infection of joint  
Osteomyelitis or osteitis

Other indications  
Bacterial infection of unspecified site